Abivax的口服UC候选药物obefazimod在3期ABTECT试验中显示对既往晚期治疗失败的患者安慰剂调整临床缓解率达34%,进一步巩固其竞争优势,估值超65亿美元。之前的临床结果今年夏天,Abivax的口服溃疡性结肠炎(UC)候选药物obefazimod的两个晚期研究结果促使其股价飙升。现在,该公司公布了该药物进一步的安全性和有效性数据,可能使其在竞争中脱颖而出。目前,该公司估值超过65...
Source LinkAbivax的口服UC候选药物obefazimod在3期ABTECT试验中显示对既往晚期治疗失败的患者安慰剂调整临床缓解率达34%,进一步巩固其竞争优势,估值超65亿美元。之前的临床结果今年夏天,Abivax的口服溃疡性结肠炎(UC)候选药物obefazimod的两个晚期研究结果促使其股价飙升。现在,该公司公布了该药物进一步的安全性和有效性数据,可能使其在竞争中脱颖而出。目前,该公司估值超过65...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.